Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Daiichinkyo CoFRA:D4S -0.47%76 Buyback Yield % is 3.03 as of Jul. 15, 2026, which is 53% above its 10-year median of 1.98. GuruFocus rates FRA:D4S with a GF Score™ of 76/100 and a GF Value™ of €32.74 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 290 Drug Manufacturers companies, Daiichinkyo Co ranks better than 93.79% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Daiichinkyo Co's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:D4S vs LLY, JNJ, ABBV: Buyback Yield % Comparison
For the Drug Manufacturers - General subindustry, Daiichinkyo Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daiichinkyo Co Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Daiichinkyo Co's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Daiichinkyo Co (FRA:D4S) has a Buyback Yield % of 3.03 as of Jul. 15, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Daiichinkyo Co and its competitors. This is 53% above median its historical median of 1.98. Over the past decade, Daiichinkyo Co's Buyback Yield % has ranged from 0.43 to 4.16. According to the industry distribution chart, Daiichinkyo Co ranks #18 out of 290 companies in the Drug Manufacturers industry, placing it in the top 6.2%.
Is Daiichinkyo Co's Buyback Yield % too high?
Daiichinkyo Co's current Buyback Yield % of 3.03 is 53% above median its 10-year median of 1.98. Over the past 10 years, this metric has ranged from a low of 0.43 to a high of 4.16. Based on the distribution chart, Daiichinkyo Co ranks #18 out of 290 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Daiichinkyo Co has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Daiichinkyo Co's Buyback Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Daiichinkyo Co ranks #18 out of 290 companies for Buyback Yield %. This places Daiichinkyo Co in the top 6% of its industry — outperforming the majority of peers. Historically, Daiichinkyo Co's own Buyback Yield % has ranged from 0.43 to 4.16 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Daiichinkyo Co and its competitors. Daiichinkyo Co's current Buyback Yield % is 3.03, which is 53% above median its own 10-year median of 1.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiichinkyo Co stock overvalued right now?
Based on GuruFocus' analysis, Daiichinkyo Co (FRA:D4S) is currently considered Significantly Undervalued. The stock's GF Value™ is €32.74, compared to a current price of €14.70 — trading 55.1% below its estimated fair value. The current Buyback Yield % is 3.03, which is 53% above median its 10-year median of 1.98. Daiichinkyo Co's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Daiichinkyo Co (FRA:D4S), the current Buyback Yield % is 3.03 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Daiichinkyo Co (FRA:D4S) Overvalued in 2026?
Based on GuruFocus' analysis, Daiichinkyo Co stock appears to be undervalued.
The current stock price of €14.70 is trading 55.1% below its estimated GF Value™ of €32.74.
GuruFocus considers Daiichinkyo Co to be Significantly Undervalued.
Key valuation signals for FRA:D4S:
Buyback Yield %: 3.03 (53% above median its 10-year median of 1.98)
GF Value™: €32.74 vs. price of €14.70 (55.1% below fair value)
No single metric tells the full story. See the FRA:D4S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu was first approved in the US in December 2019, and Datroway was first approved in January 2025.
76GF Score
Get the complete analysis for FRA:D4S
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:D4S has been successfully added to your 
